Latest / Two PhDs on a Pod / Therapeutic Plasma Exchange and the Science of Health & Longevity
Transcript
- Guru Banavar: Hey Guru. All right. Well, listen, I heard something that I almost cannot believe, which is that you can take out something harmful from your blood and then become more healthy and potentially increase your longevity and your health span. So do you do you agree with that? Yeah, yeah, I agree with that. So yeah, ⁓ that's actually the point of today's podcast. So we're gonna talk. So people have heard about different cleanses where you go on these weird protocols to cleanse your system. Well, we're gonna talk about a very direct cleansing mechanism, meaning you literally take a portion of your a significant portion of your blood out, and any compounds in there that are potentially causing you harm go out physically. So there is no indirect cleansing of the gut or any other thing. So yeah. So today's topic is. That our blood carries thousands of molecules, and many of them, when they're in too high of a concentration or if they're toxic by nature, ⁓ they are they can cause harm and they can cause inflammation, rapid aging, diseases, and so on. And so we're going to talk today about something called a therapeutic plasma exchange or TPE. It's a medical procedure that takes a very direct approach to cleansing the blood. It literally removes plasma that carries these circulating harmful molecules and replaces them with a clean fluid. So that's basically what we're gonna discuss. Amazing. Yeah, you know, when I when I first heard about it, I thought this was a little bit extreme. I mean, I I that's that was my honest view. It's that, you know, you we you heard about things like this back from you know the olden times, right? Medieval medieval times, all that kind of stuff. You know, you you take out a body fluid and you clean it up. And and all of that kind of stuff. But it's real. It's actually sounds like it's being used in the medical field for ICU, like in i intensive care unit, ⁓ where people have some extreme version of a disease, especially with autoimmune disease and so forth, or immune-related diseases of various types, inflammation. So it's amazing to me that we can now clearly demonstrate. the value and the benefit of doing something like this. So I I you know today we're gonna talk with Dr. Brad Youngren, who, by the way, is now part of VIOM. He just came into Viome after we acquired a company that he was the CEO of. The company was called Circulate. It's now part of Viome, so it's really Viome now. And so we thought it'd be great to have him on the call on the on the podcast and and talk to him about Hey, what is the science behind therapeutic plasma exchange? What's the evidence? What is the actual benefit? How easy is it to do it? Is it safe? And hopefully we will convince our audience that this is now an available therapy for those who are interested to actually improve their health and their longevity. ⁓ those who are interested, those who have a need and ⁓ have deep pockets. Awesome. So let's get into it. I'm Momo, a biochemist. And I'm Guru, an AI scientist. We're two PhDs on a pod. All right. Okay, Momo. So as usual, let's talk about what's on your radar. All right. For today, I selected foods as always. ⁓ we live to eat, so let's talk about some foods. So please share the slides that ⁓ I've prepared for today. We have two slides. ⁓ as always, I like to make foods accessible to everyone. I like to make them, you know, create a positive relationship with foods and create nutritious and delicious meals that are easy to prepare that almost anyone can prepare. And here is a way to prepare leafy greens. I think that most people have heard that leafy greens are healthy. They're absolutely packed with nutrients. But then people hear, ooh, kale, it's gross, or you know, I don't know how to make mustard greens or collard greens. I don't know what to do with it, right? And here's a very, very simple dish that I make regularly. In fact, it's my go-to dish for leafy greens, ⁓ although we put leafy greens and many other things. And I'll show you in some future episodes how I work leafy greens into other dishes. But here's one that is basically 90% leafy greens. So I just go to a local co-op and I buy two bite bunches of leafy greens and I pick whatever I want. It can be mustard greens or collard greens or kale or anything basically. ⁓ and then I will chop those up, put them in the salad spinner and wash them, and then I'll put them in a pan. And then you can see all the ingredients here. They're literally onions, garlic, sun-dried tomatoes, and your choice of leafy greens. That's it. ⁓ you can of course add salt, ⁓ which will taste better and you should you need some salt. And you can add any spices if you'd like, but The sun-dry tomatoes really add that flavor that combined with olive oil, you're really not gonna need spices. But if you really want something spicy, you can add essentially any kind of spice. You can add miso spices or Indian spices or ⁓ Mexican spices, whatever you'd like. But I just make it straight like this, and I love the flavor of sun-dry tomatoes. So I start by s just browning some onions, then I add all my leafy greens. I cook them for just a couple of minutes to lower the volume basically because you know they fill the pan when they're fresh. And then I add two big spoons of garlic and ⁓ a bunch of sun dried tomatoes. And then that cooks for just a few minutes. That's it, just until the leafy greens are soft. So it it's like it it the whole thing takes ten minutes. And now you have a side and you can basically use it instead of a salad on the side of anything. Love that. Okay. It looks it looks just phenomenal. Momo. It looks phenomenal. And as all those super healthy, super delicious. And yeah, it looks very attractive. ⁓ thank you, Guru. Okay, so let's go to the next one. Yep. ⁓ this is what I call La Fonda breakfast. And if you're ever in Santa Fe, New Mexico, I highly, highly recommend La Fonda restaurant. The hotel is also world class, but the restaurant is absolutely amazing. And they make this breakfast that I've eaten many, many times because we have a yearly genomics conference there for the last twenty years. So I've had this breakfast many times. And we also make it at home. In fact, I just had it this morning. So what is what is the stuff on the on the lower left side? The lower left is just refried beans. And we literally just refried them with salt and a little bit of chipotla seasoning or chorizo seasoning, just some chili based seasoning. Can you buy taco taco ⁓ spice mix from Trader Joe's or Any kind of chili based, I mean, but just like a little bit. ⁓ and then we have plantains, ⁓ and those are steamed and fried in olive oil. So they get really nice caramelized texture and they they provide a ton of fiber. ⁓ and they provide that complimentary flavor. And that just eggs over easy. And then you could have toast on the side if you want extra fiber and protein, which I do. So I have a whole wheat toast, of course. And If you want, you can sprinkle something like Cholula sauce or Tabasco sauce or a little bit of like ⁓ chili powder, but you don't have to. This tastes phenomenal and it's so nutrition, it's packed. And we're gonna talk about the benefits of both beans and eggs in terms of choline when we talk about the paper in the news. Amazing. All right, so that's me. So what's on your radar, Guru? Well, first of all, Momo, ⁓ here in New York and more generally in the northeast. Fall has started. Autumn has started. Yep. And autumn and or fall is my favorite season. You know, to me, you know what it feels like is a giant air conditioner just started in the sky. Everything cools down and then you feel great. You know, j you know, I I actually love going outdoors and doing a lot of activities, you know, whether whether you want to run or whether you wanna ⁓ you know, hike or whether you want to do whatever it is. Like one of my favorite hikes is in fact what flashed on the screen earlier, which is the Hudson Valley, right? I've been to so many hikes on the Hudson Valley. And you know, Momo, you were didn't believe that this was Hudson Valley, but it's actually true. This That's amazing. Yeah. If you go north on the Hudson Valley, which is Westchester County and beyond that, in the north of the So it's like a a couple of hours north of New York City, right? It's actually One hour north of New York City is where where the Hudson Valley starts. And there's many little Croton on Hudson and little towns there. But if you go two hours north, like you're suggesting, is where you start seeing the mountains, like this Bear Mountain, which is actually very close to this picture. And you can climb to the top of the, you know, the rocks basically there and ⁓ get this type of view. It's actually super amazing. I love it. And also I love the colors of fall. It just feels very artistic to me. And there's something also about the fall where I feel like it's a fresh start. It's probably because of the school season, right? The school starts in the fall. There's a lot of, you know, kids on the on our block and all of that stuff. So we see everything, you know, activities starting and stuff like that. I just feel great in fall. So I just want to mention that. And ⁓ you know, it's sort of like in my in my head, I always enjoy fall the most. I mean, a lot of people enjoy spring a lot. And I do that too, but somehow fall to me is more I don't I don't know impactful on my mind. And it it just makes me calm down, it makes me enjoy the ⁓ enjoy nature. Awesome. So Guru, ⁓ millions and millions of people visit New York City and they don't even know that this is within a two hour drive or a two hour trip. Is it possible to use public transportation to get to these hikes? Yeah, yeah, yeah. You ⁓ there is a Hudson line, the train that starts from Grand Central. There's a Hudson Line. You can take the Hudson Line and go to one of the northern stations. Okay. But there's multiple stations that you can go to one of But it's literally single train from d from Manhattan to this kind of an exposure. Correct. Correct. Amazing. In fact if on this view here, on the side of the the the river, you can when you sit and watch this valley, you can see the train pass by. The train literally goes on the side of the river. All the way to the northern part of the county and you can take the last stop there and and you can hike from there. Love it. Love it. Love it. Love it. So that was one. The other thing that's on my radar is some super cool work we did just recently scientifically about the impact of estrogen on bone health. So one of the things that we have started thinking about a lot in biome is this another acquisition of a company that we're gonna discuss In detail in one of the future episodes, where we can show that taking probiotics and prebiotics can actually improve your bone health. So we started looking for the bone health signals impacted by estrogen in the gut microbiome. So here's a chart that we came up with from our own data. It's super cool. So what it's showing is a score that Is called estrogen associated bone loss score. Higher means worse, more bone loss. Lower means less bone loss, meaning more healthy. What we see here is that's on the on the y-axis, the score on the y-axis, the x-axis is the age, age of a of an individual. So you can, you know, it's the 20s here, 30s, 40s, 50s, 60s, and 70 plus. What we are showing is how bone loss begins from. Women and men. Women are the dark blue line at the top, men is the gray line at the bottom. So for women, when they switch from the thirties to the forties, which is when they start going through menopause, most likely. Pre premenopause, yeah. Or actually perimenopause, right? The premenopause. Yeah. So, you know, some somewhere in the in their forties or maybe early fifties, people actually have that one day which is called menopause, but everything that happens before then They have a significant change to their estrogen production in the body. And when estrogen slows down, there is an impact on bone health. So what we're measuring here is that bone loss is increasing from the in the in the 40s, 50s, 60s, and 70s for women, whereas it was flat until the 40s, right? It then starts sustaining through entire midlife. That's the top blue line. Now the gray line is for men, where you see the curve is more or less flat until the sixties, and then it starts going up. So you go from the 20s, 30s, 40s, and 50s, you don't see that much of a difference in the level of bone loss for men. So the difference between women and men is that men have a 20 year advantage in terms of their bone loss. process in their in their biology. And that's a pretty significant difference. So one of the questions we're asking ourselves is how can we help women address bone loss as early as possible so that they can then minimize bone loss and keep their bone health up, right? So this is a pretty cool data point that we generated from our own data in VIOM just in the last couple of weeks. So I thought I'd just share that. It's definitely on my radar right now. I would upgrade this from pretty cool to super cool and ⁓ The audience will find out why it's super cool in one of the future episodes. Exactly. Amazing, amazing, amazing work, Guru. Awesome. So let's bring our ⁓ guest for today and have the discussion about therapeutic plasma exchange. Sounds great. Let's bring on Dr. Brad Younger. Hi, Brad. Welcome to two PhDs on a pod. I'm ex excited to finally make it on the main stage here. Appreciate you having me. I know, I know you are ⁓ You're a fervent listener of our podcast series. So you probably know everything that we've talked about before, so you can build on everything we've said before. ⁓ goodness. Well, yeah, it was a great ⁓ it was a great way to get introduced to the company to kind of catch up on all your podcasts. So there you go. So we have already ⁓ announced to our audience that ⁓ Circulate was a recent acquisition of Biome and there's a lot of things to talk about Circulate. But first, let me introduce you. So as we said before, Brad has an MD in emergency medicine, and he's gone through many. He was an army doctor in the beginning, but of course he's gone through a number of companies. I will highlight 98.6, which was a kind of a virtual care delivery organization, and they've they've done a lot of things. Actually, maybe Brad, you're one of the first users of ⁓ chatbot based. ⁓ interactions, right? ⁓ you guys did this before the LLM craze and everything started. So that's amazing. So good work on that. ⁓ and then of course you went to lead ⁓ circulate and ⁓ here you are in Vyome now. So we are very, very happy to have you. Welcome again to VIOM and to to to PhDs on a park. I appreciate it. I'm sorry I didn't bring my recipe to ⁓ show the listeners like you two do, but if I ever come back neck again I will certainly prepare better for that. So we can focus on the next slide. We'll we'll bring you back. No problem at all. So ⁓ so Brad, I think the whole idea of therapeutic plasma exchange, I'll be honest with you, when we first started talking about circulate in biome, I was, you know, reading up on ⁓ therapeutic plasma exchange. I didn't know much about it. But ⁓ I gotta tell you, the more I read about it, the more I saw why it is such a an important element of a kind of a longevity journey that somebody may have. So can you please give us the basics? What is therapeutic plasma exchange? Why would somebody want to do it? Absolutely. So it's interesting. Plasmapharesis and therapeutic plasma exchanges have been around for forty plus years, probably even longer, really. so this isn't from the from the foundational technology perspective. We have ⁓ many decades of science and safety data and knowledge about this. Really, the big shift has been moving this into new areas of indications in out of the hospital. And so at the high level, Plasmaphoresis is this sort of generalized category, and there's two main things these machines do. They can either separate the the blood into its components, which you can take off a component of the blood. So when you donate platelets or red blood cells, it's really the same machine, or plasma for that matter. So that that's where therapeutic plasma exchange comes in, and what we do is we're essentially taking off a calculated portion of plasma from your body. The other use of the machine is what's called cell collection. So that's when we get into more thinking about CAR T therapies or things where you want to like pull off a bunch of white blood cells from the patient for a variety of purposes. So that's the other thing the machine can do. And so that's really the science in the field, what's been going on in health systems and outpatient facilities for many years. Okay. Yeah. You shared this slide with us earlier. So I think this is what you're talking about, right? The separation of plasma, you discard the plasma and then you replace it with albumin. ⁓ and inject it back into the body. Well, I mean the the machine is essentially I I to to simplify it way more than I should, and I'm sure the manufacturers will get mad at me, but it's a centrifuge in a computer, right? That's really what it is. And so we separate it out, we take out the plasma out of the body, and the the machine has the ability to decide what you want to remove and what you want to return to the patient. And then because we're taking out plasma, we need to return some sort of volume back to the patient to maintain blood pressure and ⁓ And all that. So we use albumin typically for a variety of reasons. And that's the in the simplest form, that's what plasma exchange is. Taking out your plasma and we're exchanging it with, in this case, human derived albumin. ⁓ you can also, in smaller volumes, use something like normal saline. So when patients donate a small volume of red blood cells, ⁓ you could typically use normal saline or something like that as the volume replacement, but we are doing larger volume replacements, so typically we will use albumin. So so Brad, I'm gonna I'm gonna ask some of the basic questions here. Okay. So, first of all, when I first heard about it, sort of sounded like a little bit of science fiction, right? I mean, you know, you're basically taking out blood from one arm and you're cleaning up my blood, and you're sending back the clean blood back into my other arm, right? Whoa. I mean, that is a pretty, I would call it invasive procedure, but obviously there is a lot of benefit to it. That's why it came into being. And I think you mentioned that it was first used in emergency rooms, right? And in or ICUs probably for specific types of disease. So what diseases was it originally or what diseases were was it used for in the beginning? And how did it end up becoming more broad and used for even asymptomatic people who are not in the ICU who just want to optimize their health? The the machine has been used essentially if there's something that's in the plasma that you want to take out as an example, then you could imagine a potential clinical benefit, right? So ⁓ one example that has been used for years is Guillain Baret syndrome. So a better way for the listener to think about it is certain autoimmune processes where you want to remove inflammatory cytokines or autoimmune factors from the body. To reduce the pro-inflammatory event or whatever sort of disease process has been ramped up. This is one way which you can do that. ⁓ it's been used in sickle cell. There's a whole variety of things it's been used for in the past in the hospital setting. ⁓ and high the the benefit of that research is that these are in some instances critically ill patients, right? So we have a lots of interesting data in the utilization of this technology and a in a very sick population. What really changed around this was that there was a bunch of research that had been done looking at ⁓ what was now called the hero chromic parabiosis studies, where they essentially plugged in the circulatory system of genetically similar rats, one old and one young, and they reproduced these research over and over again, which essentially showed that mixing of the humors, if you will, to simplify it greatly, you end up having An event that sort of ages the young mouse and reflexively can make the older mouse younger. So that's sort of spurred an industry looking for what it is, what is in these in the blood that's having an impact on aging or inflamm aging, as many people talk about. So that really led to what's now commonly referred to the circulate trial, which was published a few years ago that I was a part of. And that that took some of that hypotheses that we knew from animal studies. And applied it in in the human domain. So the infrastructure of that study was essentially three large areas. One was objective measures, like if we do plasma exchange in humans, ⁓ where we take out plasma, what kind of impact will we see as it relates to grip strength, cognition, ⁓ things of that nature? What's something called get up and go, where you sit up from a chair and walk six feet and How fast do you do that? Balance, all those kinds of things. The second area was required a a partnership with the Bucke Institute and Dr. David Furman and Eric Redin, where we sent all the blood samples for you know advanced omics analysis, proteomics, lipomics, metabolomics, things of that nature to understand the signatures that we're seeing in these patients and were those shifting with plasma exchange. And then the third area, which ended up getting quite a bit of press, was this Think it was 34 biological clocks we ended up using ⁓ on the in the patient cohort. ⁓ we didn't really know h how to quantify which ones were better than others, so we basically used all of them that were on the commercial market at the time. So we wouldn't be having any bias there. We were happy to and we applied all the samples and all the patients pre and post against all those samples. So those are the three areas of data collection that we were able to get in the circulate trial. And that's where the foundation of From the h human health span perspective, that we got a lot of interesting data that had never been published before. ⁓ there will be some additional papers coming out from that data set, but what we did show in the large circular trial that's available in aging cell and it's free for download is was a couple main points. ⁓ the one that people ask about first typically is the latter, which is this 2.6 years of biological age reduction on average across all the biological clocks. So Yeah, yeah, Brad. I want to deep Go deeper into that, but before before I go ahead, one more basic question, okay? Sure. ⁓ so so the this parabiosis that you talked about, where you have the two rats or mice, I think. ⁓ that ⁓ you know, one of them is young, one of them is old, and if you exchange their blood, then the younger one gets older, the older one gets younger. So you also mentioned that there are these aging factors in the blood that are beyond the pro inflammatory. ⁓ activities, right? The cytokines and so on. So what are these aging related factors in the blood that is that is you believe ⁓ involved in this in this parabiosis type of activity? Well, I mean, that's a a great question. I don't think anyone in the sort of quote longevity space, biotechnology space could definitively and confidently answer it's it's likely a cascade of events. But we, you know, many different areas of this science are being looked at, interleukins, ⁓ cellular senescent cells as as two examples, right? And ⁓ so a lot of what we were trying to understand was what kind of changes were we seeing ⁓ phenotypically on the cell ⁓ as it related to SAS proteins as an example, which have a relationship to cellular senescence. Okay. ⁓ so these are the areas that ⁓ were theorized to probably have an impact because there's a larger theory Around aging, right? And you'll hear this commonly referred to at health span or longevity conferences around this idea of inflammation, right? That this inflammation itself is an age accelerating event. ⁓ and the reduction of inflammation is theorized to potentially have a positive benefit on. No, no, we we've actually seen that in the biome data, by the way, the level of inflammation as people go through the different decades of life. definitely does increase. And there's actually a number of markers in the blood that that indicate that. Yeah. I mean, it makes sense physiologically and from a medical perspective. Yeah. What's interesting is some of the research where people have gone out to try and target specific anti-inflammatory events haven't actually really always led to what was maybe expected or hoped for, like where we were seeing positive impact on morbidity or mortality. So I to me that leads to the larger question, which is this is likely a very complex cascade. Like aging is likely a complex cascade of events. ⁓ but I I agree with you, and that's one of the many reasons I'm sure we'll get into why the synergy between circulate being ⁓ brought into the Viome family, where this ⁓ knowledge and data around advanced diagnostics in now a th a potential therapeutic in certain instances would make sense to be married together. Absolutely. Let's so let's ⁓ let's let's guys cover just one more topic here for the introduction, which is so w why doesn't the body get rid of these aging biomarkers, right? So my my ⁓ comment here would be that there are kind of two types of molecules that are circulating in the blood that are contributing to our aging. One is molecules we produced and we discussed cytokines, but there's also antibodies that are related to autoimmune diseases, right? And those our body is not naturally meant to get rid of. Those are our own molecules, right? So you cannot just get rid of those naturally. So basically, TPE is the only way to get rid of those molecules. And the second class of molecules would be toxins or microplastics or anything external that we don't produce, that our liver, kidneys, and maybe other systems are supposed to remove. But for whatever reason, as we age, there are many different reasons, as we age, our body is simply less and less capable of doing that. And this is where in one swoop, you can basically remove the majority of those from the bloodstream and reduce their negative effect. Is that is that a pretty good overall summary, Brad? I think that was a great, great way you put it, Mama. That's why you have the white coat on, not me. So I appreciate that. Has has anybody actually studied the ⁓ the plasma that's removed to see what kinds of components are being removed to to and and associate that back to some of the processes we're talking about, Brad? There has been some work in that area. I think it's it's definitely an area that we would like to do more work on. It's just a question of prioritization. What we do know is that certainly there there's a lot of s of s stuff and things that are being removed into that bag. And one of the great ways to show what you're getting out of the body is to actually look in that plasma bag. So we actually looked actually in the I mean that remind that reminds me one of the one of the plasma ⁓ clinics that ⁓ that we went to over here in the New York City area. This guy was taking pictures of all of the people who who have just removed their their plasma and and they he makes them hold up the bag of plasma. And he he pointed to like this this this one looks nice, this one looks clean. This one looks like doll. He said there must be a lot of crap in that you know, in the doll is yellow lentils, not yellow. Not good in blood. Not good in blood. It's amazing when you talk to some of these ⁓ plasma exchange nurses that have been doing this for twenty five years. Like they yeah, they can look at those bags and understand, you know, and and we've had patients that have shown pictures of different stages of, you know, getting plasma exchange multiple times over a year, year and a half time. They've actually had changes in the color. It's very interesting. So ⁓ that is super interesting. Yeah, too, and I think people who get their first plasma exchange typically they'll get a photo with their plasma over over their head. You'll see sometimes see that on Instagram and places like that. Yeah. ⁓ I I would like to answer your question, Goodur, a little bit in that I think it's very likely that heavy metals are going to be removed with TPE and also mycotoxins are going to be removable with TPE. And those can cause obviously all kinds of systemic issues. So that's just on top of everything else we discussed. Got it, got it, got it. Yeah. Okay, we the only thing I'd say we did look, just because we'd done the plastic study, is we did sample plastic. the bags and we found plastics in the plasma bags, which isn't surprising related to our study that we'll probably get into. But your Momo, what you're talking about is like the many areas that need work. Like people who've been in this field for a while understand the potential impact as it relates to mercury or other heavy metals. But those papers, interestingly, have never been published. ⁓ and I I think that when people ask me why, I generally think it's just because plasma exchange has been confined is a hospital based procedure for so long. There hasn't been a lot of ⁓ impetus to do some of the research. Some of it's just implied, but it for me, like if it's implied, it should be published, right? And we should we should understand what the impact is on different heavy metals or not. So we can start to put together a a a sort of a host of indications or implications for this procedure. Yeah. So that that brings us back to the the main ⁓ result of the ⁓ of the ⁓ circulate trial that you were talking about earlier, right? So this is the, you know, where you where you measured the biological age of the participants in the study before and after TPE. And you did that not with one biological aging clock, but with how many? 32, 35? 35, I think, is yeah. 35. Yeah, there's a lot of them. You can see over here this list of all of the different biological age clocks. And ⁓ across all of them, you got a an average reduction of 2.6 years in biological age, which is a pretty amazing result. So so tell us how ⁓ how did you choose which of these biological age clocks you wanted to use for this study, for example? We chose everyone that we could get our hands on, because they're The clocks are obviously d as you probably know, done in a variety of different fashions. There's different and so from my perspective, ⁓ the best thing was just to not to try and decide which clock you thought had more clinical validity than others. And so we just did ⁓ all. Everyone we could get our hands on. We had the blood, we had the time, ⁓ we had the research infrastructure to do so. And so I think it just added to the robustness of the study. I think it would have been more challenging if we'd only picked one or two. ⁓ it gives us a much larger trends. And I'm, you know, I I always just point out for to people who are asking me about the study, there's a lot of busyness on that right side of that slide, but each of the rows is one of the clocks, right? And the columns are the different treatment arms. The first the three columns to the left are the three different treatment arms based on the frequency of TP during the procedure and whether or not they received IVIG as an adjunct. And the last one is the is the sham. So I think it's the most interesting if you look at Red as being aging and blue boxes as being a reduction in biological age. So blue is good or what we're hoping to target from the procedure. You can see there's just a lot more blue a lot more blue on the left, yes. And and a lot more red on the on the right. And a lot more red on the right. Yeah. Which is also just very interesting, right? If you think about these sham patients, they we watched them for six months and they all there was a lot of aging that went on in that in that placebo group. And it actually was what's called shamphoresis. Super interesting. Never been published as a paper in and of itself, but probably should be, was this idea that like that pr the mach the patients like had ⁓ were hooked up to the machine and the machine was turned on, it just wasn't functionally working. So like they'd they really didn't know if they were getting T P or not. So single blinded, which is kind of amazing, really. ⁓ huh. ⁓ But yeah, there's just a lot more red in the sham. And in some ways, if you'd asked me before the study, I wouldn't have expected so much of a shift in clocks, right? For just like You're talking about six months here, right? But the pre and post six months? Yeah. Right. That's that's a lot. Yeah. Yeah. It's a lot with certain clocks, not a not universally across all clocks. When you average it out, you know, I'm not sure what it is, but it's not five years on average. Correct. Yeah, I mean the right the bottom scale here shows that the dark red is about plus five and dark blue is minus five, right? So some of these people we are talking about in this some of these in some of these types of clocks, people do age, I mean can age quite a lot, apparently, even in six months, which is very interesting. I'm actually I don't remember seeing any kind of study in which somebody had used so many different types of biological aging clocks and shown the difference among them. Yeah, that is amazing. That is a wealth of information on its own. On its own. Agreed. Yep. Agreed. Good job, Brad. Amazing. Amazing. This is ⁓ this is a great this is a great piece of work. So the the the main ⁓ what are you what are your main takeaways from the from the circular trial? Well, I think what we've learned is I think we've entered this sort of renaissance period of t plasma exchange, which is really exciting, which is that ⁓ There's some human health span benefits, broadly speaking, as demonstrated through the trial. What we've learned in practice is that there's a ton of area of opportunity, ⁓ research development and data collection to understand the impact broadly on autoimmune diseases and chronic disease more broadly. And that's, I think, the next sort of frontier for plasma exchange is to understand what are these indications where people are receiving benefit. And we know. There's obviously a fair amount of plasma exchange ⁓ ongoing globally right now. And it's not just for human health span based on the circulate trial, right? Many people are using it for a variety of sort of detoxification efforts. And these need to be done in a scientific fashion, in my opinion, and published, right? So that's sort of where I think the trial is taking us, which is it showed ⁓ some really interesting findings that are very contextually relevant to human health span. And should lead to an outcropping of many future studies in this space, which I think will happen. ⁓ you know, this at the at the ASPA, which is like the big sort of scientific acepis society event. ⁓ the morning breakfast where we're talking about the frontier of plasma exchange was the largest crowd at the event. Like people are very excited to understand the potential use cases for this and how we can take the science forward, which I think is incredibly exciting. Yeah. Yeah, Brad, I think ⁓ before we go to all the other application areas of ⁓ of TPE, I think we should make sure that the safety aspects are fully disclosed, addressed and and explained to people. So one of the first questions I think most people will have is, you know, how safe is this? Has it been proven? Right? Am I am I at any kind of danger or side effects or anything else because I'm doing this? Yeah. I mean in Whether it was nine eight point six or any of the endeavors I've been involved with over the years, I really believe the foundation of any business should be in the healthcare space, needs to be ⁓ on quality and safety. I mean, if you start from that, you can gain trust with patients and have the right conversations moving forward. So we really endeavored to build that with it circulates. So we have a very large data set on our own experience on quality and safety. ⁓ but there's a whole pre-procedure process that goes into making sure that a patient ⁓ is a a good candidate for plasma exchange outside of the indications we discussed why someone may be pursuing it or interested in it, can they safely receive plasma exchange? And so we we, you know, endeavor to create the safest possible environment, make sure patients are properly selected, that they have the right ⁓ pre-evaluations performed prior to getting the procedure. So, but as I alluded to before, it ⁓ The procedure itself has been performed in hospitals for many years. Like the overall amount of data on plasma exchange is quite large. ⁓ as I s just said, there's a whole, you know, medical society, people, nurses, physicians, and others who have been spent their entire careers in this space. So I think that's a really great starting point. And ⁓ but our our interest is to continue that discussion, which is to continue to present our data, our experience, and hopefully the experience of others as well globally. So we can continue to build out this from a safety perspective so people understand that and ensure that we're doing the best thing possible for patients. Sounds great. Sounds great. So I think ⁓ I think we should definitely not not you know not only talk about the broad effects on aging and longevity, but also some specific disease areas. So I think ⁓ based on my understanding of ⁓ of the work you've done in circulate, ⁓ you did focus on a few chronic diseases, right? Can you just give us a sense of which chronic diseases you've you've ⁓ looked at, Brad? ⁓ well we're So circulates relationship as we're supporting clinics ⁓ in the functional medicine space as they are applying this against their patient population. So I think for me, I like to try and anchor around the data we have. So as an example, we have anecdotal data around different ⁓ impacts of the human exposome, right? But instead of talking about it, it's best to publish it first. So I I honestly remain a bit hesitant in the sense that I I never want to lead with data that's not published because I I just think that from a from from the perspective of what we wanted to do is circulate and now continue at Viome is to continue to lead from that perspective of of controlling the conversation from a scientific perspective that gains trust, not only with the patients, but also with the medical community. Yeah. So that's why we continue to try and find opportunities to publish. I think One of the things I'm most excited about that we built to circulate and will continue to do at VIOM is the idea of building this network. We have a piece of software that connects the clinics, which allows us to collect data in a way that's never been done as it relates to plasma exchange. And from that data collection, we'll be able to publish a multitude of papers around indications and results or lack thereof in a scientific fashion, which is the way that this needs to be done. You know, there's there are other studies I'm sure we'll get into. ⁓ the AMBAR trial, ⁓ there just came out this week in September 2026 another follow-on discussion around this AMBAR trial as it relates to Alzheimer's dementia. ⁓ there's a ton of work being done in that space. There I imagine there will be many more areas of research in the future. And then, you know, the last area is just as an adjunct of therapy. So I think that will be interesting to see what develops in the next coming years as an therapeutic plasma exchange is an adjunct therapy in the biotechnology space. But yeah, I think this is the the original Anbar trial. and you know, it it's interesting. It it predated the circulate trial. So this data was actually collected, a very large ⁓ expensive trial ⁓ was done. And it's it's interesting that in the conversation on dementia that I'm surprised it's not brought up more because ⁓ the now the number of interventions we have to impact Alzheimer's dementia is still relatively ⁓ small compared to other disease processes we treat in ⁓ in in healthcare. But the Amber trial was very interesting in the sense that we similar to the plasma exchange approach that was done in the circulate trial, a little bit different, but generally similar. ⁓ taking out plasma and replacing it with albumin and looking to see what happens to patients with various stages of Alzheimer's dementia compared to a placebo arm. I think you have that. ⁓ Yeah, this one here. Yeah, there we go. Thank you. Yeah. So this is one slide that comes from the paper and then I throw up typically when I'm speaking at conferences on the topic. And you can see here, if you're looking at just to orient the the viewer, ⁓ the the pink line is the plasma exchange treated group. So we're looking at clinical global impressions of change ⁓ measured o over ⁓ time. And the ⁓ placebo group, you can see cognitive decline, ⁓ whether it's in all patients, moderate or mild. But what's most interesting as an example, if you look at the mild group, the plasma exchange side is I would just call it relatively flat, right? We're not seeing a significant decline. I think that's probably the safest way to describe it. But I think any viewer could look at that and say there's quite a difference when you compare it to the placebo group. Yep. So that that's a very interesting finding. ⁓ The study, what I always say ⁓ when I speak at conferences is like this study needs to be repeated. This is really important information, right? ⁓ This is over a period of about a year? Mm-hmm. Yeah. Fourteen months. Fourteen months. Yeah. Okay. So that's fascinating, right? And so as we know when we get into thinking about tau and beta amyloid, ⁓ one of the things that I think, you know, we've talked about, we have not done the study, but ⁓ measuring reductions in those in some of those biomarkers associated with Alzheimer's related TP. Like that's another paper that just should be published, right? So we know what kind of impact that's having on the biomarkers that are associated with dementia. Yep. Alzheimer's in particular. By the way, by the way, Brad, I'm I'm just ⁓ also ⁓ meant to ask you this earlier, but are these people getting multiple TPs or just one TP at the beginning of this period? They're getting a number of TPs in the front period. And then right. So t tell tell us a little bit about what is the benefit of getting more than one and how often would you, you know, recommend somebody to get more than one? And and just for for reference, ⁓ the patients received six weeks of weekly conventional plasma exchange. So that's the full one that Brad is gonna talk about. And then the remaining f twelve months. They received just a monthly low volume exchange, not a full-that's a low volume plasma exchange. Yeah. So it's sort of like Yeah. So it's really the first six weeks is where the bulk of the plasma exchange took place. Yeah. It's very interesting. Yeah, I think there's some there's a a theory around so as it relates to chronic disease, typically, and this is this predates anything that happened that we did at Circulate. ⁓ if you look at protocols that are in instituted in hospitals for inflammatory chronic disease that's being treated. It's usually more than one treatment. And the reason is something that I would just say it can be loosely referred to as the container theory as a non-scientific terminology. But if you think about a container and you you in in then you remove a bunch of substance from that container, a bunch of fluid from that container. Or let's just go right to the body and say you remove a bunch of plasma. Then the body has a chance to re-equilibrate, right? Like so the plasma returns, you regenerate many factors, like coagulation factors relatively fast actually in your body ⁓ over the course of days, ⁓ not weeks. And so that's why patients could be safely brought back like on a Tuesday and a Thursday and get a second treatment. The idea is that if there's pro-inflammatory molecules, whatever you're targeting, they don't all just live in the plasma. Some are protein bound, some are in interstitial space, some are sitting in the cell wall, it depends on what example we're referring to. And so as the body recalibrates, you can come back and sort of remove more plasma and have a more significant reduction ⁓ of whatever your target molecule is, which is really interesting, right? And that makes makes sense from a physiologic perspective. So Brad, if ⁓ if a typical ⁓ male adult has two and a half liters of plasma total, ⁓ let's say, what how much plasma is removed during one TPE procedure? They have more plasma than that. But so typically we're doing one plasma volume, which is ⁓ roughly about seventy five percent of of the plasma in the body. ⁓ roughly. Okay. So you retain a quarter of it that you retain clotting factors and things of that nature with it. Got it. But what's interesting is we we didn't get into, but like we had ⁓ a a a patient that w underwent two procedures on an in a week who we were measuring their microplastics on and they had a pretty high level they came in, it dropped fairly significantly because we were measuring pre and post. They came back two days later to get a second treatment. Their microplastics level pre treatment number two is actually elevated from the post treatment one. So it went back up. And then had a very precipitous drop after the second one. So that's just that's an N of one, of course, but it's very interesting ⁓ And I think highlights some of that physiology that we just discussed. Yeah. I I I have an analogy that I that I just ⁓ came up with, which is w rinsing rice, you know. Why do you rinse rice more than once if you want to make sushi? Actually, one you I want to make Because you know, because some of the polysaccharides that are stuck to the rice, they don't come off in the first rinse, right? And so that's kind of an analogy. You need to do multiple now. There is a point of diminishing returns, ⁓ but ⁓ so Brad, you recommend six total treatments, correct? It it depends. It really d where we really want to move to is a world where we're using biomarkers ⁓ to actually be the appropriate adjuvant to the decide ⁓ what the proper treatment protocol is for patients. That makes sense. I that's where I think this science needs to get to, which is like we have the capacity to personalize therapy and that's what we need to Of course, of course. You know, ⁓ that's actually that's actually one of the big ⁓ advantages of combining circulate and biome, obviously, because it would be amazing to do a metatranscriptomic profile before and after, and then look at all the pathways that have changed in whatever direction and figure out what is the main set of benefits and also determine, depending on the individual, what makes sense to do as a follow-up. You know, how often you want to do it, how how ⁓ you know, whether you want to do low volume or regular volume, you know, all of those kinds of things, right? You can you can decide all of those things based on the metatranscotomic test. Yeah. Well that's why Or it's not metatranscotomic, even even the proti proteomic test, right? Yeah. I mean, we can do many tests, and I think it also depends on the specific patients. So for example, we talked earlier about heavy metals, maybe mycotoxins, maybe specific antibodies for like a multiple sclerosis patient or or LPS, bacterial LPS for like Alzheimer's patients or things like that. So it can be both broad, but it can also be highly specific depending on the condition you're trying to treat. So I think there's a a huge amount of opportunity here. Aaron Powell the other interesting thing we haven't talked about that I think you you two would really appreciate as well as the viewers is ⁓ this growing science around membrane filtration. Now there's not a lot of these membranes that are FDA cleared yet or f but they're they will be in in time. And I think we can see some of these in more of the global space so far. But instead of it taking the plasma out the body, you can run the blood through a filter through the with the same machine. And you can imagine that filtration can target many different things. So there's like a filter that specifically is targeting beta gal, as an example. ⁓ and so these filters have been more conceptualized around sepsis. But I think what I'm seeing in the industry is that there's a growing interest to create targeted filtration. Which I'm very interested in. I think these these could have really significant ⁓ roles when you're thinking about, hey, we specifically want to get rid of X. Can we build a filtration system that targets X? That's a very interesting technology. So I think in the next five years, the the conversation around plasma filtration will be front and center and something we talk about all the time in the space. Amazing. Amazing. Okay, so as a as a kind of a last topic ⁓ for this session. ⁓ I think we've mentioned microplastics and other kind of toxins in the blood ⁓ quite a lot. And I know, Brad, that you have also done some studies recently about it. So can you just summarize how you ⁓ saw the results of that study, the findings, and what are the takeaways for future both research and pract practice? Yeah, I mean it's such an interesting area. I've I've become such a A fanatic of reading all I can about the exposome and the impact of the exposome on the human body. I think it's it's a really interesting area to some of the things MOMA already mentioned, right? and so I just was driving one day and hearing about some of the new research coming out, New England Journal, others, about some of these cohorts post-mortem. They're finding plastics and carotid arteries, et cetera. And thought to myself, I wonder if plasma exchange is a potential modality for ⁓ targeted removal of. of microplastics. So we we did a lot of work on this. Placed a patent at the time, got all that work done and did did a ⁓ the largest and only really research trial published to date that was done on this topic. Not really knowing what obviously what the the the results would be because obviously if the plastics are not predominantly in the plasma, plasma exchange will not be the targeted approach to removing them. But ⁓ there's so much unknown science around How these plastics interact with the body? Are they an inert? Are they causing chronic disease? There's lots of theories, but all of this is association, not causation at this point. I'll come flat out and say that out front. But certainly interesting. And so we've decided the first step was let's just see if we can do a study showing that there's actually a potential way to get the plastics out of the human body if if that was so desired. And that's really what this this this ⁓ circulate plastics trial. Paper which was published in May in in the American Society of Aphores' journal, so the journal of our of our peers, and which we were really proud of, which showed that the Buck Institute, right? What's that? With the Buck Institute. Yeah, the well the Buck is in is been a a partner of of of Circulate from the beginning, which has been incredibly helpful to have their scientific rigor supporting our our research endeavors. So a hundred percent. And yeah, so we published that paper. It showed essentially if you If you have signific what I would just describe is if have significant levels of plastics, plasma exchange is a methodology which can reduce them. at the very low levels, there's a small amount of potential increase, potentially. as we've talked about before, Momo, the question is with this with the tests we have on the market, which are very early still, is when you get a four versus an eight, are those actually implying different amounts of plastics in the bloodstream? Like that's question one. But we do know that the you know we heat the plastic tubing, obviously, because patients need to be comfortable as ⁓ through the procedure. So there we've talked a lot with the manufacturers about changing the tubing and there's a lot of active ongoing discussions about that. But we already know that there's plastics in like saline bags and things like that. Those those conversations have been relatively well documented. So ⁓ but again, the whole purpose is if your if your microplastics level is five, there's no indication to get plasma exchange to Reduce your your level anyway. So really this is a conversation. And for me, it was really around this idea that there are there are legitimate occupational exposures is one example where people cannot avoid exposure to microplastics, cannot avoid exposure to PFAS for that matter, other conversation pieces here. So the idea is can we develop methodologies to help impact some of those occupations is is one example where this potentially could have value. Awesome. I love that description. Thank you, Brad. Yeah, sounds sounds great. Listen, I I think ⁓ there's just so much good work to be done in this space. And you know, now you being part of VIOM, we can take some of the science forward. Of course, we can commercialize all of these things. Very excited to do all the other work that we want to do in the provider space. You know, we need to get all our best solutions into the hands of doctors across the entire spectrum of chronic diseases. And I think with your experience in chronic disease and circulate and before that, ninety eight point six, all of those things are kind of coming together in your new role as president of our ⁓ of our pro business in bio. And I'm sure we're gonna have a lot of opportunity ⁓ and ⁓ and great time working together on getting our solutions out to the market. So thank you very much, Brad, for joining us. Thanks for having me. Excited to be a part of the team. Yeah, yeah, you'll be back. Right. Thank you very I'm bringing my food picture next time for sure. Next time. Come equipped with food. ⁓ I wanted to mention that ⁓ for the listeners, if you guys have questions, please go to our YouTube version of the episode and ask your questions where we will absolutely answer them. ⁓ because this is such a new area and it may have many, many possible useful useful ⁓ utility, I guess, clinical utilities. Yep. Absolutely. So thanks again and we will see you later. See you later, Brad. Take care. Thanks, guys. Interesting conversation with Brad. ⁓ I learned a lot. ⁓ I mean, now I'm no longer, you know, worried or afraid of this type of invasive technology. I am actually looking forward to understanding it better at maybe in the not too distant future, trying it on myself and and seeing what the impact is going to be and what the health benefits are going to be. So that was great. And I'm sure we'll have Brad back here for more. ⁓ discussion around all the work that he's gonna lead in biome and ⁓ all the clinics that we're gonna go to and so on. Yep. Yep. So so let's move to the next ⁓ section of ⁓ in the news episode which is in the news. Obviously to me the biggest news that happened in the last couple of weeks is the FDA thumbs up to the Grail gallery test. So let's just talk about that for a minute. I'll I'll give a Brief intro, please add whatever you think is appropriate. So the test from Grail, the test itself is called gallery, is designed to take a blood sample from you and look for a particular kind of circulating DNA in the blood that can identify whether there is some kind of presence of cancer. anywhere in the body. And specifically they're able to identify the organ systems to some degree of accuracy, the specific organ system from which that cancer signal is ⁓ originating from. So they are able to scan basically 50 cancers, and I think about fifteen or twenty of them are considered very frequent or, you know, high degree of mortality and ⁓ and morbidity of course, ⁓ which ⁓ is a big step in the right direction for humanity as a whole, I would I would imagine. The reason is there's so much increase in the prevalence and the incidence of cancer that we need everybody to be on the lookout. When they turn maybe 40, 45, 50, you need to start thinking about how to screen for early signals of cancer, because if you get Or if you catch the signal early, there's a lot of things you can do to reverse it, to get back to healthy states. But if you wait until it goes to, let's say, stage three or something like that, then the five year survival rate drops by a lot. And in many cases, like pancreatic cancer, for example, the amount of time you have to survive is just gonna be in the mu in a matter of months, not not even a year. So this is a super, super interesting test, I would say. It's the first time that the FDA has considered a test like this that is so broad, but the panel seems to have generally accepted the kinds of claims that Grail has put forward that they would make for their gallery test, which is great. And I think this will actually make it accessible to a much broader population because it'll be covered by insurance, hopefully, in the not too distant future. And also it'll be available in most of the places rather than just the high-end places. that it currently is. That's awesome. Yeah. I really like these news. I'd like to point out some more features. So these multi-cancer early detection tests such as gallery, and there are two others, are looking for the tiniest, tiniest trace amounts of DNA that comes from the few cancer cells or small number of cancer cells somewhere in the body. And so this technology has one foundational limit and that is that the signal is very small, especially for small cancers. And that means stages one and two typically have a very poor sensitivity. And that's that's a big drawback, but that is the state of the art today. And as the technology, you know, progresses, we'll know we'll do better. But I just want to caution people that this is not this is not like a high sensitivity ⁓ sort of a test. The the sensitivity on average for stages one is something on the order of twenty or thirty percent, meaning that they will only catch twenty or thirty percent of the people who have stage one cancer on average. That's unfortunate, but that is the start of the technology. ⁓ the second thing I want to mention is that these these tests are quite expensive. So the grail test is about eight, nine hundred dollars per test. But if you do it once a year on your HSA account, it's okay potentially. And if insurance covers it, that'll be even great. And there are two other competing tests that I think peop people should research and compare. ⁓ the other one is called Cancer Guard by Exact Scientist Sciences. And it's very comparable in performance and cost. And then there's the brand new one just came out last week, which is KARIS or CARIS life sciences. It's called a CARIS test. And it's $3,500. I'm not sure why it's so much more expensive, but we'll we'll see what the performance is like. So yeah, these are nice options. And I also want to add that VIOME is starting to work on ⁓ you know, we already have one cancer test. ⁓ we're gonna come out with another cancer detect test now in October. And I want to mention that What we're doing at VIOM is fundamentally different is that we're not looking for those trace trace amounts of DNA coming from tumor cells, so circulating tumor DNA. We're actually looking at other signals that are supposed to be much more robust. And that's, for example, why our cancer test for oral and throat cancer has 90% sensitivity. So out of a hundred people that have stage one oral or throat cancer, we identified in ninety percent of the people. That's really extraordinary. Exactly, Mama. Thank you. Thank you for highlighting the fact that, you know, the you know, the stage one sensitivity of the multi-cancer early detection test is in fact very low, which people may not catch, right? Even even though it's called the multi-cancer early detection test, the early detection sensitivity is really not. It's the it's the weakest point of the test. But at the same time, you know, we didn't have anything like this in the past. So we have something, so it's the beginning. Off a trend which I think will keep improving over time. Yeah. ⁓ our job is really to highlight all the positives and negatives, and there's a lot of positives here, and it's just the start of this technology. And so people just need to understand what are the pluses and minuses and make a choice whether they want to take it or not. All right, let's go to the next news, which is a paper I wanted to highlight. And ⁓ I think our audience is very familiar with the fact that VIOM is all about the chemical signaling within the body, because our body functions on chemical signaling. And so for example We don't tell people what microbes they have in their gut microbiome. And the reason is that my immune system doesn't understand at all the fact that humans have identified a microorganism and get gave it a name, right? That like my immune system doesn't care about that. It doesn't have consciousness and understanding of the English language to say, I have Fecaliobacterium prysnitia in my gut microbiome. So I'm gonna be ⁓ you know, I'm not gonna raise inflammation. It listens for chemical signals. And here's another of Hundreds and hundreds of examples where it's the biochemical functions of the microbiome that our immune system listens for and acts upon. And so in this paper, we are showing a mechanistic ⁓ discovery where P researchers discovered that acetylcholine, which is a neurotransmitter, one of the major neurotransmitters in the brain, is actually produced by the gut bacteria. This has been unknown. And that acetylcholine actually stimulates the local mucosal immune system. To release a type of antibody called IgA. It's the it's the mucosal antibody. And so they show then mechanistically that if you feed choline, which is a nutritional ingredient, to these bacteria, they will produce acetylcholine. They will stimulate this IgA production, which will redu which will basically reduce infections, GI infections. So we all know that, you know, people go out and have dinner. And one person gets sick, another person doesn't get sick. And this is one of the w mechanisms. It's the fact that your gut microbiome protects you against gut pathogens. And here's a mech just molecular mechanism of that. And I also highlighted on the right side what the sources of choline. So choline is like a super, super beneficial molecule for cognitive health and many other benefits that I think we touched upon in other ⁓ episodes. But here specifically, it stimulates this sort of mucosal immunity in the gut. ⁓ and the good sources of choline are meat, and then for example, beef liver would be the highest concentration of choline. But eggs are one of the best sources. And then when we go to plant based sources, soybeans and beans in general have very high concentration of s of choline. So if you eat plenty of soybeans and beans in your diet, you're completely set. You you get plenty of ⁓ daily ⁓ you know, choline consumption. But if you can eat eggs, they're a great source. So I Here's a highlight where we're connecting micronutrients in specific foods with specific microbial functions that affect our immune system, that affect our health, just like we've highlighted many times before. Beautiful. Beautiful. What what a great story. Thank you. ⁓ also just to just to make sure that ⁓ I understand some of the basics here, right? You also hear about the fact that you don't want to over consume choline, right? Because of other reasons as well. Right. So you need to have Not too little, not too much. You need to have the right level as always in biology. Great point. And it depends on your microbiome functions, right? And it depends on your microbiome functions. If your great point, Guru. So if your microbiome functions tend to convert choline into trimethylamine, and that trimethylamine is produced in excess, then it may cause ⁓ atherosclerosis or cardiovascular disease. And so yes, balancing that, ⁓ you know, getting right to the point where it's Very beneficial and not yet harmful, but not going beyond that point is key. And there's only one way to know that. And that is the s the the gut the stool test from biome. There's no exact there's no other way to know that. And so but that's one of the one of one of the hundreds of reasons why we developed this test is to give people into the the insight into what's going on in their gut microbiome. But yes, great point. Perfect. Okay. So with that, I think the next segment we're gonna go to is the Viome Monthly Challenge. Momo, do you have an announcement to make? I do. So we have a Vio Monthly Challenge winner. ⁓ and that is a ⁓ user called Scrapper2 Happy. So at Scrapper2Happy, if you're listening to this, please email us at podcast at Viome.com. And you're the winner of the monthly challenge with full body intelligence kit from VIOM. So please email us and I will send you the kit. ⁓ but here's here's ⁓ how the user won the the challenge. So she asked the question that she was really intrigued by the possibility that certain oral bacteria, which we discussed with Dr. Ed Zuckerberg in a lot in the last episode, that certain oral bacteria can get into the brain and lead to cognitive decline. And she was wondering, well, why don't we just use antibiotics to kill the bacteria and prevent that cognitive decline? Okay, so my explanation is that, well, antibiotics don't target specific bacteria. They're they just wipe out the entire microbial community. And unfortunately, some of these bacteria that produce these toxins are actually more resistant to most of the antibiotics, such that you're actually going to do more damage than than benefit. And what I want to what I want people to really think about is instead of trying to destroy a community, the natural way is for the rest of the bacteria that are in your oral cavity to be protective and to balance the community and balance these potentially pa pathogenic bacteria. And so what you really want to do is nourish your community and you want to nourish that protective community. And that's what that's why some people don't get Alzheimer's, or many people don't get Alzheimer's, because they have enough protective bacteria in their oral microbiome. I think that strongly that using mouthwash, for example, or antibiotics ⁓ can negatively affect the overall community, which then enables the growth of these pathogenic bacteria and can lead to mild cognitive impairments. There's another there's another, you know, ⁓ connection which is with the gut microbiome. If you take oral antibiotics, you will also destroy your gut microbiome. And I just want to point out people in this direction that you you guys can do research now with LLMs, but basically there are many, many large studies showing that cumulative use of antibiotics in your lifetime raises the risk of many chronic diseases and cancers. That's a super strong connection. Because because you're you may be wiping out basically all the commensals as well. Yeah, exactly. That's probably the mechanism. And so be careful with using antibiotics. And actually, to address the specific question, st studies have been published, very large studies, where people have hypothesized, hey, can antibiotic use actually lower the incidence of dementia? And they found that not to be the case. So y antibiotic use does not decrease onset of dementia or mild cognitive impairment. So in from a very large data set, data show not to be the case. So I would say don't try this at home. So congratulations off congratulations to Ed Scrapper to Happy. Yep. Congratulations and ⁓ great question and a lovely discussion around this. Let me just wrap up the episode by saying that next time we're going to be talking about AI and machine learning, which is very hot. Also, there's a lot of hype around this, but we will be talking about what is all of this method or method set, meaning a bag of tools that we can use for improving our understanding of biology, health, and more broadly, knowledge in the human in the in the human community overall. So there's a lot of things to be talked about and Momo and I are going to explore a lot of examples and talk about the general principles. We're going to talk about the trends. We're going to give you some Hard facts about what is going on right now and where it's probably gonna lead. A lot of exciting things to talk about. With that, I think we'll close this episode. Just a second. I'm super excited about that episode. So it's not that we are gonna talk about it. I'm gonna be asking hard questions and Guru gonna is gonna be the expert because he's been the leading AI expert and especially now in biology field for a decade plus. So I'm super excited to actually ex that that that you with the right questions and and and good ⁓ you know prompting Guru is going to be able to answer really important questions so that people can be equipped with the knowledge to when they see a new ⁓ test or a new company that's claiming AI, they can actually distinguish, you know, what's true, what's not, and fact check it and so on. So I'm really excited about that, Guru. That because you can explain things so well. So all right. Thank you. I'm Momo, a biochemist. And I'm Guru, an AI expert who's gonna take the stage next episode. Yep. And we are We're two PhDs on a pod. Bye bye. Bye. Two PhDs on a pod is a Viome Health Science Podcast production, written and hosted by Viome CTO Guru Banavar and Viome CSO Momo Vuisic. Produced and edited by Lisa Shomo. Podcast Art by Kevin Wu. If you enjoyed today's episode, like and subscribe for new episodes every other week. We'll see you next time.